James Stuart Ferriss

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3379112/publications.pdf

Version: 2024-02-01

759233 713466 21 666 12 21 citations h-index g-index papers 21 21 21 1238 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	When $\hat{a} \in \mathbb{R}^n$ never-events $\hat{a} \in \mathbb{R}^m$ occur despite adherence to clinical guidelines: The case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gynecologic Oncology, 2010, 116, 374-377.	1.4	111
2	Multi-Gene Expression Predictors of Single Drug Responses to Adjuvant Chemotherapy in Ovarian Carcinoma: Predicting Platinum Resistance. PLoS ONE, 2012, 7, e30550.	2.5	95
3	Cancer in Obese Women: Potential Protective Impact of Bariatric Surgery. Journal of the American College of Surgeons, 2009, 208, 1093-1098.	0.5	89
4	Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study. Gynecologic Oncology, 2015, 139, 17-22.	1.4	74
5	Molecular Requirements for Transformation of Fallopian Tube Epithelial Cells into Serous Carcinoma. Neoplasia, 2011, 13, 899-IN16.	5.3	66
6	Use of Image-Guided Stereotactic Body Radiation Therapy in Lieu of Intracavitary Brachytherapy for the Treatment of Inoperable Endometrial Neoplasia. International Journal of Radiation Oncology Biology Physics, 2013, 85, 129-135.	0.8	40
7	Uterine serous carcinoma: key advances and novel treatment approaches. International Journal of Gynecological Cancer, 2021, 31, 1165-1174.	2.5	40
8	Evaluation of EVI1 and EVI1s (\hat{l} "324) as potential therapeutic targets in ovarian cancer. Gynecologic Oncology, 2010, 118, 189-195.	1.4	24
9	Cervical Stromal Invasion Predicting Survival in Endometrial Cancer. Obstetrics and Gynecology, 2010, 116, 1035-1041.	2.4	21
10	Temozolomide in Advanced and Recurrent Uterine Leiomyosarcoma and Correlation With O6-Methylguanine DNA Methyltransferase Expression. International Journal of Gynecological Cancer, 2010, 20, 120-125.	2.5	19
11	Patient perceptions and willingness to participate in clinical trials. Gynecologic Oncology, 2016, 142, 520-524.	1.4	19
12	Image-guided high-dose-rate intracavitary brachytherapy in the treatment of medically inoperable early-stage endometrioid type endometrial adenocarcinoma. Brachytherapy, 2017, 16, 1144-1151.	0.5	15
13	Does Significant Medical Comorbidity Negate the Benefit of Up-front Cytoreduction in Advanced Ovarian Cancer?. International Journal of Gynecological Cancer, 2012, 22, 762-769.	2.5	10
14	Incisional hernia formation and associated risk factors on a gynecologic oncology service: an exploratory analysis. Archives of Gynecology and Obstetrics, 2016, 294, 805-811.	1.7	10
15	Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers. Current Treatment Options in Oncology, 2019, 20, 75.	3.0	10
16	Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report. Cancer Chemotherapy and Pharmacology, 2010, 66, 265-267.	2.3	8
17	Diffuse large B cell lymphoma of the cervix with rectal involvement. Gynecologic Oncology Reports, 2014, 10, 1-4.	0.6	6
18	Treatment of vulvar and vaginal dysplasia: plasma energy ablation versus carbon dioxide laser ablation. International Journal of Gynecological Cancer, 2021, 31, 1410-1415.	2.5	3

#	Article	IF	CITATIONS
19	Localized cavernous hemangioma of the uterus involving adenomyotic foci. Journal of Cancer Research and Therapeutics, 2011, 7, 69.	0.9	2
20	Iterative approach to journal club. Postgraduate Medical Journal, 2020, 96, 496-499.	1.8	2
21	Systematic Review of Intraoperative Assessment Tools in Minimally Invasive Gynecologic Surgery. Journal of Minimally Invasive Gynecology, 2021, 28, 692-697.	0.6	2